Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXBASU study of dapagliflozin plus exenatide in type 2 diabetes awaiting bariatric surgery
2017-001454-33Phase 2Active
- Sponsor
- Dr. Albert Lecube Torello
- Start
- Jun 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin and exenatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Dr. Albert Lecube Torello. Started Jun 2017; status: active.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2017-001454-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001454-33.